Mixed HCV infection and reinfection in people who inject drugs--impact on therapy.
about
Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic AnalysisAPASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.The impact of HCV therapy in a high HIV-HCV prevalence population: A modeling study on people who inject drugs in Ho Chi Minh City, VietnamThe Impact of Direct-Acting Antivirals in the Hepatitis C-Sustained Viral Response in Human Immunodeficiency Virus-Infected Patients With Ongoing Barriers to Care.Direct-acting antiviral agents for HCV infection affecting people who inject drugs.Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs.Hepatitis C virus whole genome sequencing: Current methods/issues and future challenges.Successful Treatment of Mixed Hepatitis C Genotypes in a Cirrhotic Patient With an All-Oral, Interferon-Free RegimenElimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there?HCV reinfection incidence among individuals treated for recent infection.Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.High-resolution melting combines with Bayes discriminant analysis: a novel hepatitis C virus genotyping method.Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study.Recommendations for the management of hepatitis C virus infection among people who inject drugs.Hepatitis C cross-genotype immunity and implications for vaccine developmentQUENTIN: reconstruction of disease transmissions from viral quasispecies genomic data.Dynamics of HCV epidemiology in Aydin province of Turkey and the associated factors.Prevalence of mixed genotype hepatitis C virus infections in the UK as determined by genotype-specific PCR and deep sequencing.Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis.Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies.Risk factors for familial clustering of hepatitis C virus infection in a Chinese Han population: a cross-sectional study.Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis
P2860
Q28552507-78F3CA54-0E2E-479A-A35B-4349B034F605Q30250088-890110BE-5A65-4401-9D59-012E2D0F23ADQ33663998-56B9F129-9D21-43AC-B48A-1A214046871CQ36382060-C73E54DA-DA7A-4D62-A7BE-AABCFB8BF806Q38613271-AC8CEF26-276E-410A-8333-9CEF50CF8D3BQ38661825-D9116B4D-75DB-4850-A11D-7455111964C3Q38692113-2612D2E9-6EB2-4E2C-BDDD-D74B7FDB5053Q38805659-6BB3164E-3358-4B4F-9409-175F94AE69BBQ38863925-652C26E6-ACA0-4097-98FB-B08E88818999Q40092669-FC010A27-35C4-47FB-9768-28AE06C8F40CQ40393982-BFD911A6-8D9E-4B6E-99D7-E286DE40ACB8Q40565832-5BF36854-3070-4B10-BE75-BF1A6C389437Q40675001-0702B3ED-420D-47A4-8B15-E0341421FB14Q40959924-F24BE841-3457-4F84-9E14-07521491D579Q41047662-DA3F9B2B-9CD9-4407-AD78-CB65B4E4B3DBQ42364607-0284FFA5-EC1B-4D15-AD60-D90674C0A24FQ47205333-E56BA0E4-87FD-483C-8103-C5A569985339Q47560767-0E6155A2-D0D5-4477-9414-EA697A4AACD6Q47560950-DCB59AE8-3A59-429A-8A54-A5605EEA2A35Q47594606-F7C44A0E-7307-47F4-A04F-A1DC79768655Q49953662-0CD63514-089D-400C-9869-43D717035E82Q55396689-34F936D7-6C93-432A-B00F-26727D85C12DQ56782091-99050410-B543-473F-A0DF-635F0E3BA4E1
P2860
Mixed HCV infection and reinfection in people who inject drugs--impact on therapy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Mixed HCV infection and reinfection in people who inject drugs--impact on therapy.
@en
type
label
Mixed HCV infection and reinfection in people who inject drugs--impact on therapy.
@en
prefLabel
Mixed HCV infection and reinfection in people who inject drugs--impact on therapy.
@en
P2860
P50
P356
P1476
Mixed HCV infection and reinfection in people who inject drugs--impact on therapy.
@en
P2093
Gregory J Dore
Jason Grebely
P2860
P2888
P304
P356
10.1038/NRGASTRO.2015.36
P407
P577
2015-03-17T00:00:00Z